India’s diabetes challenge is growing fast, and access to modern treatment options matters more than ever. In a new move aimed at improving care, Abbott has partnered with Novo Nordisk India to bring Extensior, a semaglutide-based therapy, to Indian patients. The medicine is based on semaglutide, the same molecule used in Ozempic, and is designed for adults with type 2 diabetes.
Through this collaboration, Abbott will commercialise Extensior in India, combining Novo Nordisk’s expertise in GLP-1 science with Abbott’s wide reach across the country.
WHAT THE PARTNERSHIP MEANS
Under the agreement, Novo Nordisk will develop and manufacture semaglutide, while Abbott will handle its commercial presence in India under the brand name Extensior.
The aim is simple: help more people with type 2 diabetes access evidence-based treatment options that go beyond basic blood sugar control.
This collaboration brings together Novo Nordisk’s long-standing work in GLP-1 therapies and Abbott’s strong on-ground presence in India, especially in diabetes medicines, diagnostics and nutrition.
WHY SEMAGLUTIDE MATTERS
Extensior is approved as an add-on to diet and exercise for adults with type 2 diabetes. As a GLP-1 receptor agonist, it offers a wide range of benefits for people living with the condition.
Semaglutide has shown strong HbA1c reduction, weight-loss benefits, and reduced risk of cardiovascular and kidney events in people with type 2 diabetes.
Its safety and effectiveness are backed by more than 44 clinical trials and over 10 real-world studies across diabetes, obesity, heart, liver and kidney disease.
Globally, semaglutide has been in use for close to a decade, with over 49 million patient-years of experience across all its products.
WHAT ABBOTT AND NOVO NORDISK SAY
Kartik Rajendran, Managing Director, Abbott India Limited, said:
“India is facing one of the world’s fastest-growing diabetes burdens, and addressing this challenge requires continuous innovation and strong partnerships.
The launch of Extensior builds on Abbott’s longstanding focus on holistic diabetes management, from medicines to diagnostics, and from continuous glucose monitoring to diabetes-specific nutrition.”
Vikrant Shrotriya, Managing Director, Novo Nordisk India, added: “Semaglutide represents one of the most important scientific advances in diabetes care in recent decades.
Our partnership with Abbott will help make this innovative molecule accessible to a greater number of people living with type 2 diabetes in India.”
AVAILABILITY IN INDIA
Extensior will be part of Abbott’s expanding advanced diabetes portfolio and is expected to be available to Indian patients soon.
The launch is positioned as a step towards wider access to modern diabetes therapies in a country with one of the highest diabetes burdens globally.
